Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2006-06-06
2006-06-06
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S455000, C435S456000, C424S093100, C424S093200, C424S093600
Reexamination Certificate
active
07056699
ABSTRACT:
A vector capable of transducing non-dividing and/or slowly dividing cells is provided, wherein the vector is a lentiviral LTR-deleted vector. Also provided is a method for producing a protein of interest in a non-dividing or slowly dividing cell by transducing the cell with a lentiviral LTR-deleted vector and expressing the protein of interest in the cell. In addition, target cells containing the lentiviral LTR-deleted vector are provided.
REFERENCES:
patent: 5344923 (1994-09-01), Verma et al.
patent: 5359035 (1994-10-01), Habermann
patent: 5604114 (1997-02-01), Haseltine et al.
patent: 6235522 (2001-05-01), Kingsman et al.
patent: 6541219 (2003-04-01), Kingsman et al.
patent: 6924123 (2005-08-01), Kingsman et al.
patent: WO 89/12109 (1989-12-01), None
patent: WO 92/07945 (1992-05-01), None
patent: WO 92/21750 (1992-12-01), None
patent: WO 94/12520 (1994-06-01), None
patent: WO 95/28493 (1995-10-01), None
patent: WO 95/30755 (1995-11-01), None
patent: WO 95/32300 (1995-11-01), None
patent: WO 95/34670 (1995-12-01), None
patent: WO 96/05319 (1996-02-01), None
patent: WO 96/14332 (1996-05-01), None
patent: WO 96/28563 (1996-09-01), None
patent: WO 96/37621 (1996-11-01), None
patent: WO 96/37623 (1996-11-01), None
patent: WO 97/18319 (1997-05-01), None
patent: WO 97/48277 (1997-12-01), None
W. French Anderson, Nature, vol. 392, pp. 25-30.
J. L. Fox, Nature Biotechnology, vol.18, pp. 142-144.
E. B. Kmiec, American Scientist, vol. 87, pp. 240-247.
Ross, et al., Human Gene Therapy, vol. 7, pp. 1781-1790.
Salmons et al., Human Gene Therapy, vol.4, pp. 129-141.
Verma et al., Nature, vol. 389, pp. 239-242.
Brenner et al., Biochimica et Biophysica Acta, 2003, vol. 1640, pp. 1-24.
Marshall, Science, 2003, vol. 299, p. 320.
Anderson, Nature, 1998, vol. 392, pp. 25-30.
Quinonez et al., DNA and Cell Biology, 2002, vol. 21, No. 12, pp. 937-951.
Chang et al. (1993) Human Immunodeficiency Viruses Containing Heterologous Enhancer/Promoters are Replication Competent and Exhibit Different Lymphocyte Tropisms. Journal of Virology, vol. 67,pp. 743-752.
Verma et al. (1997) Gene Therapy-Promises, Problems, and Prospects. Nature, vol. 39, pp. 239-242.
Eck et al. (1996) “Gene-Based Therapy. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9thEd., Chapter 5”.
Paulus et al. “Self-contained, Tetracycline-Regulated Retroviral Vector System for Gene Delivery to Mammalian Cells,” Journal of Virology. vol. 70(1), Jan. 1996, pp. 62-67.
Parolin et al. (1996) “Use of cis- and trans-Acting Viral Regulatory Sequences To Improve Expression Of Human Immunodeficiency Virus Vectors In Human Lymphocytes,” Virology, vol. 222, pp. 415-522.
Marasco et al., “Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gpl20 single-chain antibody”,Proc. Natl. Acad. Sci, vol. 90, 1993, Natl. Acad. Sci., Washington, D.C.
Nature Genetics, vol. 8, Oct. 1994, pp. 148-154, Kaplitt et al., “Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain”.
Science, vol. 266, Nov. 25 1994, pp. 1399-1403, During et al., “Long-Term Behavioral Recovery in Parkinsonian Rats by an HSV Vector Expressing Tyrosine Hydroxylase”.
Neuroreport, vol. 6, No. 1, Dec. 30, 1994, Horellou et al., “Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson'disease”.
Journal of Neurochemistry, vol. 56, No. 3, 1991, pp. 1030-1036, Owens et al., “L—3, 4—Dihydroxyphenylalanine Synthesis by Geneticall Modified Schwann Cells”.
Science, vol. 272, Apr. 12, 1996, pp. 263-267, Naldini et al., “In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector”.
Journal of Virology , Jul 1988, pp. 2464-2473, Bowtell et al., “Comparison of Expression in Hemopoietic Cells by Retroviral Vectors Carrying Two Genes”.
Blood, vol. 84, No. 6, Sep. 15, 1994, pp. 1812-1822, Correll et a., “Retroviral Vector Design for Long-Term Expression in Murine Hematopoietic Cells In Vivo”.
Cell, vol. 39, Dec. 1984, pp. 459-467, Emermann et al., “Genes with Promoters in Retrovirus Vectors Can Be Independently Suppresed by an Epigenetic Mechanism”.
Molecular and Cellular Biology, Dec. 1991, pp. 5848-5859, Ghattas et al., “The Encephalomyocarditis Virus Internal Ribosome Entry Site Allows Efficient Coexpression of Two Genes from a Recombinant Provirus in Cultered Cells and in Embryos”.
Proc. Natl. Acad. Sci. USA, vol. 86, May 1989, pp. 3519-3523, Hantzopoulos et al., “Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector”.
The Journal of Biological Chemistry, vol. 266, No. 13, May 5, 1991, pp. 8416-8425, Hatzoglou et al., “Hormonal Control of Interacting Promoters Introduced into Cells by Retroviruses”.
The Journal of Biological Chemistry, vol. 263, No. 33, Nov. 25, 1988, pp. 17798-17808, Hatzoglou et al., “Hormonal Regulation of Chimeric Genes Containing the Phosphoenolpyrusvate Carboxykinase Promoter Regulatory Region in Hepatoma Cells Infected by Murine Retroviruses”.
Human Gene Therapy 3, 1992, pp. 381-390, Li et al, “Comparison of the Expression of a Mutant Dihydrofolate Reductase under Control of Different Internal Promoters in Retroviral Vectors”.
Virology 195, 1993, pp. 1-5, McLachlin et al., “Factors Affecting Retroviral Vector Function and Structural Integrity”.
Molecular and Cellular Biology, Apr. 1988, pp. 1803-1808, Overell et al., “Stably Transmitted Triple-Promoter Retroviral Vectors and Their Use in Transformation of Primary Mammalian Cells”.
Proc. Natl. Acad. Sci. USA, vol. 88, Jun. 1991, pp. 4626-4630, Scharfmann et al., “Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants”.
Gene Therapy, 1994 1, pp. 307-316, Vile et al., “A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes”.
Virology 171, 1989, pp. 331-341, Xu et al. “Factors Affecting Long-Term Stability of Moloney Murine Leukemia Virus-Based Vectors”.
Proc. Natl. Acad. Sci. USA, vol 84, Aug. 1987, pp. 5197-5021, Yee et al., “Gene expression from transcriptionally disabled retroviral vectors”.
Journal of Virology, Sep. 1991, pp. 4985-4990, Adam et al., “Internal Initiation of Translation in Retroviral Vectors Carrying Piconavirus 5′ Nontranslated Regions”.
Proc. Natl. Acad. Sci. USA, Aug. 1993, vol. 90, pp. 7889-7893, Marasco et al., “Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gpl20, single-chain antibody”.
Cell, vol. 54, Sep. 9, 1988, pp. 841-853, Wiederrecht et al., “Isolation of the Gene Encoding the S. cerevisiae Heat Shock Transcription Factor”.
Nature, vol. 362, Apr. 29, 1993, pp. 852-855, Dekker et al., Solution structure of the POU-specific DNA-binding domain of Oct-1.
Genes & Development 1, 1988, pp. 1582-1599, Sturm et al., “The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain”.
FEBST Letters, vol. 262, No. 1, Mar. 1990, pp. 82-86, Aumailley et al., “Identification of the Arg-Gly-Asp sequence in laminin A chain as a latent cell-binding site being exposed in fragment P1”.
Gene Therapy 1995, 2, pp. 750-756, Wickham et al, “Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs”.
Proc. Natl. Acad. Sci. USA, vol. 83, May 1986, pp. 3194-3198, Yu et al. “Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells”.
Research Paper, Dec. 1995
Kingsman Alan John
Kingsman Susan Mary
Guzo David
Kowalski Thomas J.
Oxford Biomedia (UK) Limited
LandOfFree
Lentiviral LTR-deleted vector does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lentiviral LTR-deleted vector, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lentiviral LTR-deleted vector will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3665292